Summary
A blood test called Galleri, which aims to detect multiple cancers early, did not meet its key goal in a major NHS trial. The test's creators, Grail, noted potential benefits, but experts remain cautious until it is proven to save lives.
Key Facts
- The Galleri blood test was tested on 142,000 NHS patients to find cancers early.
- It looks for fragments of DNA from tumors in the bloodstream.
- The main goal of the trial was not achieved, but some data showed potential benefits.
- Grail, the company behind the test, announced a decrease in some stage four cancers.
- The trial's results were not the main target but sparked debate among experts.
- Full data will be presented at a conference by the American Society of Clinical Oncology this year.
- The NHS will review the results to decide on future use of such tests.
